Search results
DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOP
PharmiWeb· 20 hours agoDefence’s CNRI-H project will focus on the synthesis and evaluation of novel constructs, variations of 111In-AccuTOX®-Trastuzumab.